Navigation Links
Intellikine Completes $51 Million Financing
Date:7/8/2009

ships to deliver the best medicines for patients and the greatest value for our investors."

"Intellikine has rapidly assembled one of the best pipelines against a very important class of drug targets," commented Markus Goebel, Managing Director, Novartis Venture Funds. "I am very much looking forward to working with the management team and board to build the company and, in particular, to establish clinical proof of concept for the company's lead programs."

About Intellikine

Intellikine is a leader in the discovery and development of novel, small molecule therapies targeting the PI3K/mTOR pathway for the treatment of cancer, inflammation and autoimmune diseases. Intellikine has discovered multiple classes of proprietary compounds that selectively target isoforms of the PI3K pathway. The company's most advanced compound, INK128, a potent and selective TORC1/2 inhibitor with exceptional drug-like properties is scheduled to enter Phase I clinical evaluation within 12 months. Intellikine is developing PI3K-delta/gamma dual-selective inhibitors for the treatment of cancer, inflammatory and respiratory diseases and PI3K-alpha/beta selective inhibitors for the treatment of solid tumor malignancies as well as other isoform-selective inhibitors of the PI3K/mTOR pathway. Intellikine is a private company based in La Jolla, California. For more information, please visit the company's website at www.intellikine.com.


'/>"/>
SOURCE Intellikine, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Funxional Successfully Completes Initial Clinical Trial of FX125L, an Anti-Inflammatory Drug With a Novel Mechanism of Action
2. Verenium Completes Amendment to 8% Senior Convertible Notes
3. Johnson & Johnson Completes Initial Tender Offer for Cougar Biotechnology
4. Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carboplatin Head and Neck Cancer Trial
5. Excalibur International Marine (49% Owned by EFT BioTech Holdings) Completes Inaugural Passenger Crossing of Taiwan Strait
6. EFT BioTech Holdings, Inc.s Sea Vessel Completes Inaugural Passenger Voyage Across the Taiwan Strait
7. Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cutaneous T-cell Lymphoma
8. Cordex Completes Production of ATPace(TM) Clinical Trial Material
9. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
10. Brooks Instrument Completes Acquisition of Celerity's Instrumentation Division
11. Sinovac Completes Construction of H1N1 Virus Seed Bank

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...f., Nov. 6 ,, 3Q09... of Qutenza(TM) E.U. Marketing Authorization to As...ess in commercial readiness activities Expanded m...r, Marketing; and Director, Commercial Operations ...r and Audit Committee chairman , Upcoming 2...
(Date:11/6/2009)... The agenda for Arrowhead’s 2010 Persona...et to take place on February 22-24, 2010 in Philad...erence we will highlight key issues in forming par...eir experiences. , Minnea...or Arrowhead’s 2010 Personalized Medicine P...
(Date:11/5/2009)...., Nov. 5 DSM Pharmaceutical Produ...ng alliance with Galenix, Saint Jean D,Illac, Fran...le manufacturing partner for Galenix commercial pr...ll collaborate on business development opportuniti..., based on the strength of Galenix in drug product...
(Date:11/5/2009)...v. 5 Transgenomic, Inc. ...al results for the quarter ended September 30, 200...n the tables that follow. ,, Third Quarter 200...00 or $0.01 per share for the third quarter of 200...er share for the third quarter of 2008. ,, Net...
Breaking Biology Technology:NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7
...NOVATO, Calif., Oct. 29 Diamics announced today t...te Europeene) approval for its,Pap-Map(TM) System ...es,that the product has met EU health, safety and ...d workplace safety. Granted in the Netherlands, th...d in the European Union,(EU) and other countries a...
...SAN MARCOS, Calif., Oct. 29 Cliniqa Corporation (...stic products, is pleased to,announce the acquisit...,Inc. "Raichem" (San Diego, CA), a wholly owned su...D). Raichem is a manufacturer of clinical,diagnost...s, calibrators,and controls. "The acquisition of R...
...Strategy to Focus on Sales Growth and Product Deve...ns,Inc. (OTC Bulletin Board: BLFS), a leading deve...age and cryopreservation media products for,cells,...outsourced product,manufacturing, warehousing, and..., a subsidiary of NextPharma Technologies Inc. Bio...
Other Biology Technology:Diamics Receives European CE Mark Approval for Its Pap-Map(TM) System for Cervical Cancer Screening 2Cliniqa Corporation Completes Asset Acquisition of Reagents Applications, Inc. 2BioLife Solutions Outsourcing Manufacturing, Warehousing, and Order Fulfillment to Bioserv Corporation 2BioLife Solutions Outsourcing Manufacturing, Warehousing, and Order Fulfillment to Bioserv Corporation 3
(Date:11/4/2009)...Call/ -- BIO-key International, Inc. (OTC Bulletin...identification software is showcasing donor and pa...ce being held at the New Orleans Convention Center...ds-on product demonstrations of its state-of-the-a...at 5 PM on Monday, October 26, Peter Lux, manager ...
(Date:11/4/2009)...versity of North Carolina at Chapel Hill School of...ancisco have developed and experimentally tested a...ting drugs. , The researchers developed a comput...tures of all known drugs are to the naturally occu...isease targets within the cell. In a study publish...
(Date:11/4/2009)...oe Software, Inc., the commercial arm of the Open ...openmicroscopy.org ), is proud to announce its co...ogy,s exciting new project titled "The Cell: An Im...imulus grant through the National Institutes of He...of the American Reinvestment and Recovery Act, to ...
Breaking Biology News(10 mins):BIO-key(R) International Exhibiting at AABB TXPO 2Study points to new uses, unexpected side effects of already existing drugs 2Glencoe Software to Support the ASCB 'Stimulus Grant' to Build Virtual Image Library of the Cell 2Hisamitsu Pharmaceutical Co Inc Begins Tender Offer for All Outstanding Shares of Noven Pharmaceuticals Inc 52504 1Hisamitsu Pharmaceutical Co Inc Begins Tender Offer for All Outstanding Shares of Noven Pharmaceuticals Inc 52504 2President Obamas Health Care Plan 3A Too Big Too Expensive Too Rushed 52500 1President Obamas Health Care Plan 3A Too Big Too Expensive Too Rushed 52500 2President Obamas Health Care Plan 3A Too Big Too Expensive Too Rushed 52500 3Glenmark Brings to the Notice of the Authorities Irregularities of the Clinical Investigator at its Jamnagar Site in Gujarat 52496 1Glenmark Brings to the Notice of the Authorities Irregularities of the Clinical Investigator at its Jamnagar Site in Gujarat 52496 2
...ls that seem identical may belong to completely di...hers at the University of Gothenburg, Sweden, who ... most common segmented worms is actually two types...t the variety of species on the earth could be con...lking about a large number of species that have ex...
...problems associated with environmental issues impr...sis of student performance on PISA 2006--an intern...re the best informed about environmental science a...ut the environmental challenges facing the world i...east informed in these areas are the most wildly o...
...ternational research team headed by two researcher...been awarded a US$900,000 grant to help unravel th...esponsible for controlling the expression of genes... number of diseases, including many cancers. , Th... different regions of the DNA. These proteins int...
Other Biology News:Animals that seem identical may be completely different species 2Students least informed about environmental science are most optimistic 2Students least informed about environmental science are most optimistic 3Research team wins funds to unravel a DNA mystery 2
7500 Series ICP-MS ChemStation Upgrade from Agilent Technologies
Safety Glasses Dispensers from Terra Universal, Inc.
Apparel Dispenser from Terra Universal, Inc.
...A expression profiling and built on the flexible a... platform. These microarrays are available as part...g Service. Probe Content The Mammals microRNA M... unique mature sequences). The comprehensive probe...
Biology Products: